

UAE Human Insulin Market By Indication (Type I Diabetes, Type II Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection), By Region, Competition Forecast & Opportunities, 2027

https://marketpublishers.com/r/UF8D4AB6E2C1EN.html

Date: February 2023

Pages: 79

Price: US\$ 4,400.00 (Single User License)

ID: UF8D4AB6E2C1EN

Abstracts

UAE human insulin market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027, on the account of increasing instances of diabetes among the population of the country. Growing advancement in the pharmaceutical industry and surging demand for pharmaceutical products to control high blood sugar levels among the population are further driving the growth of the UAE human insulin market in the upcoming five years. Moreover, the increasingly sedentary lifestyle of the adult and young adult population that give rise to the lifestyle diseases like obesity, blood pressure, and blood sugar disorders, also facilitates the growth of the UAE human insulin market in the next five years.

Synthetic insulin designed and manufactured in laboratories is known as human insulin. In the laboratories, human insulin is created by growing the insulin proteins in Escherichia Coli (E-Coli) bacteria and later deriving the insulin from bacteria. The bacterial culture is grown under a controlled environment maintaining the hygiene and



purity of the bacterial culture. Before the discovery of human insulin, animal insulin was used in a purified form of porcine (swine/pigs). Human insulin is majorly available in two forms regular insulin and Neutral Protamine Hagedorn insulin.

Diabetes Instances Drive Market Growth

Increasing instances of diabetes among the population of the country is the most important factor driving the growth of the UAE human insulin market in the upcoming five years. In the year 2021, among every 1000 population mark of the country, over 990 people suffer from diabetes. The cases of diabetes are higher among the geriatric population of the country. One in every 5 people aged over 69 years suffers from diabetes in the country. By 2019, over 19% of the adult population aged between 20 years to 79 years were suffering from type II diabetes. The country stands at the 10th largest population suffering from diabetes on the world scale.

Experts even mention diabetes as a silent pandemic in the country since the death count because of diabetes is much higher as compared to COVID-19. People suffering from diabetes were strictly advised to monitor their health conditions before and after vaccination since the immune system of a diabetic patient is drastically affected. Thus, increasing the risks of COVID-19 infection multiple folds.

Pharma Advancement For Insulin Drug Delivery Promises Growth

Research and product development is taking place in the country. The government is aiding the research institutes and pharmaceutical designers to advance the drugs and drug delivery systems such that efficient insulin delivery systems can be deduced, which would further aid the growth of the UAE human insulin market in the upcoming five years.

Trabolsi Research Group at NYU Abu Dhabi has developed a revolutionary technology in insulin oral delivery system that can orally administer insulin and avoid side effects caused by the otherwise process of subcutaneous delivery of insulin through frequent injection. The researchers have developed gastro-resistant imine-linked-covalent organic framework nanoparticles (nCOFs) by using prepared layers of nanosheets with insulin loaded in between layers. The system is biocompatible, highly stable in the stomach, specific, and able to deliver the right amount of insulin. Thus, providing a future scope for further development and enhancing the market growth along with it.

Market Segmentation



The UAE human insulin market is segmented by indication, route of administration, type, onset time, products, competitional landscape, and regional distribution. Based on indication, the market is differentiated between type I diabetes and type II diabetes. By route of administration, the market is fragmented into subcutaneous, nasal, intravenous, transdermal, oral, and others. Based on type, the market is further segmented into basal, bolus, pre-mixed, biosimilar, and traditional. The onset time market segment is further defined into rapid-acting, short-acting, intermediate-acting, long-acting, ultra-long acting, pre-mixed, and inhaled. Based on products, the market is bifurcated into insulin pens, insulin pumps, infusion systems, and injection. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Abu Dhabi region, Dubai region, Sharjah region, and the rest of UAE.

Company Profile

Novo Nordisk Pharma Gulf FZ-LLC, Sanofi UAE, Baxter International UAE, B. Braun Medical Gulf FZ – LLC, Eli Lilly, and Company UAE, Becton Dickinson And Company UAE, Gulf Pharmaceutical Industries P.S.C. (Julphar), among others is a partial list of major market players of the companies responsible for the growth of UAE human insulin market.

Report Scope:

In this report, UAE human insulin market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

UAE Human Insulin Market, By Indication:

Type I Diabetes

Type II Diabetes


UAE Human Insulin Market, By Route of Administration:

Subcutaneous


Nasal

Intravenous











Contents

- 1. PRODUCT OVERVIEW
- 2. RESEARCH METHODOLOGY
- 3. IMPACT OF COVID-19 ON UAE HUMAN INSULIN MARKET
- 4. VOICE OF CUSTOMER
- 5. EXECUTIVE SUMMARY
- 6. UAE HUMAN INSULIN MARKET OUTLOOK
- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Indication (Type I Diabetes, Type II Diabetes)
- 6.2.2. By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others)
 - 6.2.3. By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional)
- 6.2.4. By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
 - 6.2.5. By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection)
 - 6.2.6. By Company (2021)
 - 6.2.7. By Region
- 6.3. Product Market Map

7. DUBAI HUMAN INSULIN MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Indication
 - 7.2.2. By Route of Administration
 - 7.2.3. By Type
 - 7.2.4. By Onset Time
 - 7.2.5. By Products



8. SHARJAH HUMAN INSULIN MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Indication
 - 8.2.2. By Route of Administration
 - 8.2.3. By Type
 - 8.2.4. By Onset Time
 - 8.2.5. By Products

9. ABU DHABI HUMAN INSULIN MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Indication
 - 9.2.2. By Route of Administration
 - 9.2.3. By Type
 - 9.2.4. By Onset Time
 - 9.2.5. By Products

10. MARKET DYNAMICS

- 10.1. Drivers
- 10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

- 12. POLICY & REGULATORY LANDSCAPE
- 13. UAE ECONOMIC PROFILE

14. COMPETITIVE LANDSCAPE

- 14.1. Competition Outlook
- 14.2. Company Profiles
- 14.2.1. Novo Nordisk Pharma Gulf FZ-LLC
- 14.2.2. Sanofi UAE



- 14.2.3. Baxter International UAE
- 14.2.4. B. Braun Medical Gulf FZ LLC
- 14.2.5. Eli Lilly and Company UAE
- 14.2.6. Becton Dickinson And Company UAE
- 14.2.7. Gulf Pharmaceutical Industries P.S.C. (Julphar)

15. STRATEGIC RECOMMENDATIONS



I would like to order

Product name: UAE Human Insulin Market By Indication (Type I Diabetes, Type II Diabetes), By Route of

Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By

Products (Insulin Pens, Insulin Pumps, Infusion System, Injection), By Region,

Competition Forecast & Opportunities, 2027

Product link: https://marketpublishers.com/r/UF8D4AB6E2C1EN.html

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/UF8D4AB6E2C1EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms



& Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970